Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
ALK (Anaplastic lymphoma kinase)
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related tests:
‹
FoundationOne® CDx (110)
Guardant360® CDx (54)
MSK-IMPACT (21)
FoundationOne® Liquid CDx (20)
VENTANA ALK (D5F3) CDx Assay (13)
FoundationOne® Heme CDx (10)
TruSeq®Amplicon - Cancer Panel (5)
Oncomine™ Pan-Cancer Cell-Free Assay (4)
OncoDEEP (3)
TruSight Oncology 500 Assay (3)
Guardant360 TissueNext™ (2)
Oncomine™ Comprehensive Assay v3M (2)
Vysis ALK Break Apart FISH Probe Kit (2)
AmoyDx® Pan Lung Cancer PCR Panel (1)
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)
Idylla™ GeneFusion Assay (1)
InVisionFirst®-Lung (1)
OncoCompass™ Target (1)
Tempus xT Assay (1)
Trailblaze Pharos™ (1)
ACTOnco
ASPYRE-Lung
AVENIO Tumor Tissue Surveillance Kit
AVENIO Tumor Tissue Targeted Kit
AVENIO ctDNA Surveillance Kit
AVENIO ctDNA Targeted Kit
AmoyDx® EML4-ALK Fusion Gene Detection Kit
AmoyDx® Essential NGS Panel
AmoyDx® HANDLE Classic NGS Panel
AnchorAIM® 10 Gene Test for Individualized Treatment of Lung Cancer
AnchorAIM® 72 gene detection for individualized treatment of solid tumors
Archer® FusionPlex® Lung Kit
Archer® FusionPlex® Lymphoma
Archer® FusionPlex® Oncology Research Kit
Archer® FusionPlex® Sarcoma kit
Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit
Archer® VariantPlex® Solid Tumor Kit
Archer™ FusionPlex™ Core Solid Tumor Panel
Archer™ VARIANTPlex™ Complete Solid Tumor panel
Archer™ VARIANTPlex™ Pan Solid Tumor panel
BROCA Cancer Risk Panel
Blueprint Genetics Comprehensive Hereditary Cancer Panel
BrainTumorNext®
CancerNext-Expanded®
CustomNext-Cancer®
EGFR/KRAS/ALK Gene Mutation Detection Kit
Early-stage NSCLC Panel
Find It®
Follow It®
FusionPlex® Dx
FusionPlex® Pan Solid Tumor v2 panel
FusionPlex™ Pan-Heme panel
GALEAS™ Tumor
GeneStrat® test
HDPCR NSCLC RUO Assay
HTG EdgeSeq ALKPlus Assay EU
HTG EdgeSeq Lung Fusions Assay
InVisionSeq™
Ion AmpliSeq Colon and Lung Cancer Research Panel v2
Labcorp® Plasma Complete™
Labcorp® Plasma Focus™
Liquid Biopsy Solid Tumor
Liquid Trace™ Solid Tumor
LiquidGx™
LiquidHALLMARK®
LiquidPlex™
Lung Cancer 8-Gene Kit
Lung Cancer Mutation Panel
LungCure™ CDx
MI Tumor Seek™
NeXT Dx™ Test
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
NexCourse®
Northstar Select™
NovoFocus™ CRC 2.0
NovoFocus™ NSCLC 2.0 Test
NovoPM™ 2.0
OncoGuide™ NCC Oncopanel System
OncoGxOne™
OncoKey™ SL 525 Plus Assay
OncoKey™ SL 60 Plus Assay
OncoPanel™ Assay
OncoPlus
OncoSTRAT&GO
OncoScreen™ Focus CDx Tissue Kit
Oncomine Dx Express Test
Oncomine Focus Assay
Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
Oncomine Precision Assay
Oncomine Solid Tumor DNA Kit
Oncomine Tumor Mutation Load Assay
Oncomine™ Comprehensive Assay Plus
Oncomine™ Lung cfDNA Assay
Oncotype MAP™ Pan-Cancer Tissue Test
OptiSeq™ Lung Cancer Panel
OptiSeq™ Pan-Cancer Gene Panel
PGDx elio™ plasma resolve assay
PGDx elio™ tissue complete assay
PredicineCARE™
PredicineHEME™
QFusion™ EML4-ALK and KIF5B-ALK Fusion Gene Detection Test
Resolution ctDx Lung Assay™
SOPHiA DDM Dx RNAtarget Oncology Solution
SOPHiA DDM™ Solid Tumor Plus Solution
StrataNGS™ Test
Target Selector™ NGS Lung Panel
Tempus xF Assay
Tempus xF+ Panel
Tempus xG+
Theralink Assay
ThyGeNEXT® + ThyraMIR®
Todai OncoPanel (TOP)
TruSight Oncology Comprehensive
VarMap™ Pan-Cancer NGS Panel
ZytoLight® SPEC ALK Dual Color Break Apart Probe
oncoReveal™ Core LBx
oncoReveal™ Essential LBx
oncoReveal™ Fusion LBx Panel
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
oncoReveal™ Solid Tumor v2 Panel
FoundationOne® CDx (110)
Guardant360® CDx (54)
MSK-IMPACT (21)
FoundationOne® Liquid CDx (20)
VENTANA ALK (D5F3) CDx Assay (13)
FoundationOne® Heme CDx (10)
TruSeq®Amplicon - Cancer Panel (5)
Oncomine™ Pan-Cancer Cell-Free Assay (4)
OncoDEEP (3)
TruSight Oncology 500 Assay (3)
Guardant360 TissueNext™ (2)
Oncomine™ Comprehensive Assay v3M (2)
Vysis ALK Break Apart FISH Probe Kit (2)
AmoyDx® Pan Lung Cancer PCR Panel (1)
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)
Idylla™ GeneFusion Assay (1)
InVisionFirst®-Lung (1)
OncoCompass™ Target (1)
Tempus xT Assay (1)
Trailblaze Pharos™ (1)
ACTOnco
ASPYRE-Lung
AVENIO Tumor Tissue Surveillance Kit
AVENIO Tumor Tissue Targeted Kit
AVENIO ctDNA Surveillance Kit
AVENIO ctDNA Targeted Kit
AmoyDx® EML4-ALK Fusion Gene Detection Kit
AmoyDx® Essential NGS Panel
AmoyDx® HANDLE Classic NGS Panel
AnchorAIM® 10 Gene Test for Individualized Treatment of Lung Cancer
AnchorAIM® 72 gene detection for individualized treatment of solid tumors
Archer® FusionPlex® Lung Kit
Archer® FusionPlex® Lymphoma
Archer® FusionPlex® Oncology Research Kit
Archer® FusionPlex® Sarcoma kit
Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit
Archer® VariantPlex® Solid Tumor Kit
Archer™ FusionPlex™ Core Solid Tumor Panel
Archer™ VARIANTPlex™ Complete Solid Tumor panel
Archer™ VARIANTPlex™ Pan Solid Tumor panel
BROCA Cancer Risk Panel
Blueprint Genetics Comprehensive Hereditary Cancer Panel
BrainTumorNext®
CancerNext-Expanded®
CustomNext-Cancer®
EGFR/KRAS/ALK Gene Mutation Detection Kit
Early-stage NSCLC Panel
Find It®
Follow It®
FusionPlex® Dx
FusionPlex® Pan Solid Tumor v2 panel
FusionPlex™ Pan-Heme panel
GALEAS™ Tumor
GeneStrat® test
HDPCR NSCLC RUO Assay
HTG EdgeSeq ALKPlus Assay EU
HTG EdgeSeq Lung Fusions Assay
InVisionSeq™
Ion AmpliSeq Colon and Lung Cancer Research Panel v2
Labcorp® Plasma Complete™
Labcorp® Plasma Focus™
Liquid Biopsy Solid Tumor
Liquid Trace™ Solid Tumor
LiquidGx™
LiquidHALLMARK®
LiquidPlex™
Lung Cancer 8-Gene Kit
Lung Cancer Mutation Panel
LungCure™ CDx
MI Tumor Seek™
NeXT Dx™ Test
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
NexCourse®
Northstar Select™
NovoFocus™ CRC 2.0
NovoFocus™ NSCLC 2.0 Test
NovoPM™ 2.0
OncoGuide™ NCC Oncopanel System
OncoGxOne™
OncoKey™ SL 525 Plus Assay
OncoKey™ SL 60 Plus Assay
OncoPanel™ Assay
OncoPlus
OncoSTRAT&GO
OncoScreen™ Focus CDx Tissue Kit
Oncomine Dx Express Test
Oncomine Focus Assay
Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
Oncomine Precision Assay
Oncomine Solid Tumor DNA Kit
Oncomine Tumor Mutation Load Assay
Oncomine™ Comprehensive Assay Plus
Oncomine™ Lung cfDNA Assay
Oncotype MAP™ Pan-Cancer Tissue Test
OptiSeq™ Lung Cancer Panel
OptiSeq™ Pan-Cancer Gene Panel
PGDx elio™ plasma resolve assay
PGDx elio™ tissue complete assay
PredicineCARE™
PredicineHEME™
QFusion™ EML4-ALK and KIF5B-ALK Fusion Gene Detection Test
Resolution ctDx Lung Assay™
SOPHiA DDM Dx RNAtarget Oncology Solution
SOPHiA DDM™ Solid Tumor Plus Solution
StrataNGS™ Test
Target Selector™ NGS Lung Panel
Tempus xF Assay
Tempus xF+ Panel
Tempus xG+
Theralink Assay
ThyGeNEXT® + ThyraMIR®
Todai OncoPanel (TOP)
TruSight Oncology Comprehensive
VarMap™ Pan-Cancer NGS Panel
ZytoLight® SPEC ALK Dual Color Break Apart Probe
oncoReveal™ Core LBx
oncoReveal™ Essential LBx
oncoReveal™ Fusion LBx Panel
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
oncoReveal™ Solid Tumor v2 Panel
›
Associations
(661)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ensartinib
Sensitive: A1 - Approval
ensartinib
Sensitive
:
A1
ensartinib
Sensitive: A1 - Approval
ensartinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ceritinib
Sensitive: A1 - Approval
ceritinib
Sensitive
:
A1
ceritinib
Sensitive: A1 - Approval
ceritinib
Sensitive
:
A1
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
iruplinalkib
Sensitive: A1 - Approval
iruplinalkib
Sensitive
:
A1
iruplinalkib
Sensitive: A1 - Approval
iruplinalkib
Sensitive
:
A1
ALK wild-type
Non Small Cell Lung Cancer
ALK wild-type
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
EGFR mutation + ALK negative + TMB-H
Non Small Cell Lung Cancer
EGFR mutation + ALK negative + TMB-H
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
ALK negative
Non Small Cell Lung Cancer
ALK negative
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK G1202R
Non Small Cell Lung Cancer
ALK G1202R
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
EGFR expression + ALK positive
Non Small Cell Lung Cancer
EGFR expression + ALK positive
Non Small Cell Lung Cancer
PD-L1 inhibitor
Resistant: A2 - Guideline
PD-L1 inhibitor
Resistant
:
A2
PD-L1 inhibitor
Resistant: A2 - Guideline
PD-L1 inhibitor
Resistant
:
A2
EGFR expression + ALK positive
Non Small Cell Lung Cancer
EGFR expression + ALK positive
Non Small Cell Lung Cancer
PD1 inhibitor
Resistant: A2 - Guideline
PD1 inhibitor
Resistant
:
A2
PD1 inhibitor
Resistant: A2 - Guideline
PD1 inhibitor
Resistant
:
A2
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login